文献速递骨软组织肉瘤与黑色素瘤

恩考芬尼联合比美替尼治疗BRAF突变黑色素瘤的生活质量:COLUMBUS III期研究

Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).
PubMed 文献 · Eur J Cancer · 2021-06-04

COLUMBUS研究显示,在BRAF突变晚期黑色素瘤患者中,恩考芬尼联合比美替尼相比维莫非尼改善了无进展生存和总生存且耐受性良好。生活质量分析显示,联合治疗组FACT-M和EORTC QLQ-C30整体健康状况评分较维莫非尼组改善,且非住院患者生活质量恶化延迟。

要点

  • 联合治疗组FACT-M评分较维莫非尼组改善3.03分(p<0.0001)。
  • 联合治疗组EORTC QLQ-C30整体健康评分较维莫非尼组改善5.28分(p=0.0042)。
  • 非住院患者相比住院患者生活质量恶化延迟,联合治疗组10%恶化风险降低。

核心结论

  • 恩考芬尼联合比美替尼相比维莫非尼的疗效改善转化为患者感知健康状况的积极影响。

研究设计与样本

  • COLUMBUS为两部分、开放标签、随机III期研究,PART-I纳入577例BRAF突变黑色素瘤患者,按1:1:1随机接受恩考芬尼联合比美替尼、恩考芬尼或维莫非尼治疗。
  • 主要终点为无进展生存,次要终点包括通过EQ-5D、EORTC QLQ-C30和FACT-M问卷评估的健康相关生活质量。

主要发现

  • 联合治疗组FACT-M评分较维莫非尼组基线后差异为3.03(p<0.0001),EORTC QLQ-C30整体健康状况评分差异为5.28(p=0.0042),提示患者状态有意义的改变。
  • 非住院患者相比住院患者生活质量恶化延迟,EORTC QLQ-C30风险比(95%CI)为1.16(0.80; 1.68),FACT-M为1.27(0.81; 1.99)。
  • 两组中联合治疗均有利于降低10%恶化风险。

临床怎么用

  • 对于BRAF突变晚期黑色素瘤患者,恩考芬尼联合比美替尼在改善生存的同时可维持或改善健康相关生活质量。
  • 临床决策中可考虑联合治疗对患者感知健康状况的积极影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In COLUMBUS, treatment with encorafenib plus binimetinib in patients with advanced BRAF-mutant melanoma showed improved progression-free and overall survival with favourable tolerability compared to vemurafenib treatment. Here, results on health-related quality of life (HRQoL) are presented. METHODS: COLUMBUS was a two-part, open-label, randomised, phase III study in patients with BRAF-mutant melanoma. In PART-I, 577 patients were randomised (1:1:1) to encorafenib plus binimetinib, encorafenib or vemurafenib. The primary objective was to assess progression-free survival. As a secondary objective, HRQoL was assessed by the EQ-5D, the EORTC QLQ-C30 and the FACT-M questionnaires. Furthermore, time to definitive 10% deterioration was estimated with a Kaplan-Meier analysis and differences in mean scores between groups were calculated with a mixed-effect model for repeated measures. Hospitalisation rate and the impact of hospitalisation on HRQoL were also assessed. RESULTS: Patients receiving the combination treatment showed improvement of their FACT-M and EORTC QLQ-C30 global health status scores, compared to those receiving vemurafenib (post-baseline score differences: 3.03 [p < 0.0001] for FACT M and 5.28 [p = 0.0042] for EORTC QLQ-C30), indicative of a meaningful change in patient's status. Furthermore, a delay in the deterioration of QoL was observed in non-hospitalised patients compared to hospitalised patients (hazard ratio [95% CI]: 1.16 [0.80; 1.68] for EORTC QLQ-C30 and 1.27 [0.81; 1.99] for FACT-M) and a risk reduction of 10% deterioration, favoured the combination in both groups. CONCLUSION: The improved efficacy of encorafenib plus binimetinib compared to vemurafenib, translates into a positive impact on the perceived health status as assessed by the HRQoL questionnaires. The study is registered with ClinicalTrials.gov, number NCT01909453 and EudraCT number 2013-001176-38.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gogas H, Dummer R, Ascierto PA, et al. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). Eur J Cancer. 2021. PMID: 34091420. doi:10.1016/j.ejca.2021.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。